Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency syndrome that results from abnormal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function. This defect leads to recurrent catalase-positive bacterial and fungal infections as well as associated granuloma formation. We review the case of a 2-year-old boy who presented with ascites and fever of an unknown origin as manifestations of CGD. Cultures were negative for infection throughout his course, and CGD was suspected after identification of granulomas on peritoneal biopsy. Genetic testing revealed a novel mutation in the CYBB gene underlying his condition. This paper highlights the importance of considering CGD in the differential diagnosis of fever of unknown origin and ascites in children. 1. Introduction Chronic granulomatous disease (CGD) results from the inability of neutrophils to complete the first step of the respiratory burst pathway, generation of superoxide, with the downstream consequence of impaired microbe killing. CGD leads to recurrent and potentially lethal infections. Pneumonia is the most common infection before diagnosis (47%) [1] and occurs in the majority (79%) of patients within four years of diagnosis [2]. Lymphadenitis is the second most common infection before diagnosis (45%) [1], and subcutaneous abscess is the second most common infection that occurs within 4 years of diagnosis (43%) [2]. Other presenting infections include osteomyelitis, liver and perirectal abscesses, enteritis, and septicemia [1]. CGD can, in very rare circumstances, present with ascites [3]. The incidence of CGD is estimated to be between 1/200,000 and 1/250,000 US births [2]. Most affected individuals are male because approximately 70% of mutations are X-linked recessive; the remaining 30% of cases are autosomal recessive [1, 2, 4]. In normal individuals, inflammatory stimuli prompt nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (a lysosomal enzyme encoded on chromosome 22) to produce superoxide. Superoxide is converted to hydrogen peroxide via superoxide dismutase and then to hypochlorous acid (by myeloperoxidase), which is lethal to bacteria [5]. Individuals with CGD are able to utilize hydrogen peroxide made by microbes and convert it to hypochlorous acid to preserve microbe killing, yet catalase-positive bacteria can prevent this step by degrading the hydrogen peroxide. Thus, catalase-positive organisms such as Staphylococcus aureus are the most common microbial sources of infection; other common pathogenic organisms in patients with CGD are
References
[1]
B. Martire, R. Rondelli, A. Soresina et al., “Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study,” Clinical Immunology, vol. 126, no. 2, pp. 155–164, 2008.
[2]
J. A. Winkelstein, M. C. Marino, R. B. Johnston et al., “Chronic granulomatous disease: report on a national registry of 368 patients,” Medicine, vol. 79, no. 3, pp. 155–169, 2000.
[3]
M. Castro, L. Balducci, C. Ciuffetti, V. Lucidi, A. Torre, and S. Bella, “Ascites as an unusual manifestation of chronic granulomatous disease in childhood,” Pediatria Medica e Chirurgica, vol. 14, no. 3, pp. 317–319, 1992.
[4]
C. Casimir, M. Chetty, M. C. Bohler et al., “Identification of the defective NADPH-oxidase component in chronic granulomatous disease: a study of 57 European families,” European Journal of Clinical Investigation, vol. 22, no. 6, pp. 403–406, 1992.
[5]
“Chronic granulomatous disease,” in Hematology: Basic Principles and Practice, R. Hoffman, Ed., Churchill Livingstone, Philadelphia, Pa, USA, 2009.
[6]
S. M. Holland, “Chronic granulomatous disease,” Clinical Reviews in Allergy and Immunology, vol. 38, no. 1, pp. 3–10, 2010.
[7]
D. Roos, D. B. Kuhns, A. Maddalena, et al., “Hematologically important mutations: X-linked chronic granulomatous disease (third update),” Blood Cells Molecules and Diseases, vol. 45, no. 3, pp. 246–265, 2010.
[8]
H. Berendes, R. A. Bridges, and R. A. Good, “A fatal granulomatosus of childhood: the clinical study of a new syndrome,” Minnesota Medicine, vol. 40, no. 5, pp. 309–312, 1957.
[9]
B. H. Landing and H. S. Shirkey, “A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes,” Pediatrics, vol. 20, no. 3, pp. 431–438, 1957.
[10]
“Chronic granulomatous disease,” in Nelson Textbook of Pediatrics, R. Kliegman, Ed., Elsevier, Philadelphia, Pa, USA, 2011.
[11]
R. L. Baehner and D. G. Nathan, “Quantitative nitroblue tetrazolium test in chronic granulomatous disease,” The New England Journal of Medicine, vol. 278, no. 18, pp. 971–976, 1968.
[12]
C. L. Epling, D. P. Stites, T. M. McHugh, H. O. Chong, L. L. Blackwood, and D. W. Wara, “Neutrophil function screening in patients with chronic granulomatous disease by a flow cytometric method,” Cytometry, vol. 13, no. 6, pp. 615–620, 1992.
[13]
F. Morel, “Molecular aspects of chronic granulomatous disease. ‘the NADPH oxidase complex’,” Bulletin de l'Academie Nationale de Medecine, vol. 191, no. 2, pp. 377–392, 2007.
[14]
F. Defendi, E. Decleva, C. Martel, P. Dri, and M. J. Stasia, “A novel point mutation in the CYBB gene promoter leading to a rare X minus chronic granulomatous disease variant—impact on the microbicidal activity of neutrophils,” Biochimica et Biophysica Acta, vol. 1792, no. 3, pp. 201–210, 2009.
[15]
J. Rae, P. E. Newburger, M. C. Dinauer et al., “X-linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase,” The American Journal of Human Genetics, vol. 62, no. 6, pp. 1320–1331, 1998.
[16]
T. M. Rossi, J. Cumella, D. Baswell, and B. Park, “Ascites as a presenting sign of peritonitis in chronic granulomatous disease of childhood,” Clinical Pediatrics, vol. 26, no. 10, pp. 544–545, 1987.
[17]
S. Subramaniam, D. Tuman, A. R. Rausen, and S. D. Douglas, “‘Ascites’ and inguinal hernias: unusual presentation for chronic granulomatous disease of childhood,” The Mount Sinai Journal of Medicine, vol. 41, no. 4, pp. 566–569, 1974.
[18]
C. B. Foster, T. Lehrnbecher, F. Mol et al., “Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease,” Journal of Clinical Investigation, vol. 102, no. 12, pp. 2146–2155, 1998.
[19]
D. B. Kuhns, W. G. Alvord, T. Heller et al., “Residual NADPH oxidase and survival in chronic granulomatous disease douglas,” The New England Journal of Medicine, vol. 363, no. 27, pp. 2600–2610, 2010.